Pancreatic Cancer Research

ResearcherKyoto UniversityNo recent work listed

Shinji Üemoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0126-9346; OpenAlex author ID A5072168969. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 21

  1. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A pros… Co-author DOI 10.1002/cam4.6470↗
  2. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Co-author DOI 10.1186/s12885-022-09244-6↗
  3. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. Co-author DOI 10.1186/s12885-022-09619-9↗
  4. SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2. Co-author DOI 10.1111/cas.15162↗
  5. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Co-author DOI 10.7554/elife.55117↗
  6. Impact of the preoperative bone mineral density on the outcomes after resection of pancreatic cancer. Last author DOI 10.1007/s00595-019-01954-y↗
  7. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective… Last author DOI 10.1016/j.suronc.2020.10.010↗
  8. Time-frequency analysis of serum with proton nuclear magnetic resonance for diagnosis of pancreatic cancer. Last author DOI 10.1038/s41598-020-79087-3↗
  9. Effects of Alkalization Therapy on Chemotherapy Outcomes in Advanced Pancreatic Cancer: A Retrospective Case-Control Study. Co-author DOI 10.21873/invivo.12080↗
  10. Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice. Co-author DOI 10.1136/gutjnl-2017-315425↗
  11. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2018.03.039↗
  12. Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer. Last author DOI 10.1245/s10434-017-6077-y↗
  13. A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement. Last author DOI 10.21873/anticanres.12172↗
  14. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Last author DOI 10.1007/s00595-016-1310-z↗
  15. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-015-0864-x↗
  16. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Last author DOI 10.1016/j.surg.2015.02.002↗
  17. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.204↗
  18. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable progn… Co-author DOI 10.1007/s00066-014-0610-8↗
  19. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Co-author DOI 10.1097/mpa.0000000000000050↗
  20. Alpha-fetoprotein-producing pancreatic cancer cells possess cancer stem cell characteristics. Last author DOI 10.1016/j.canlet.2011.04.023↗
  21. Laparoscopic common hepatic artery ligation and staging followed by distal pancreatectomy with en bloc resection of celiac artery for advanced pancreatic cance… Last author DOI 10.1111/j.1758-5910.2011.00105.x↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshihiko Masui · 10 shared papers, 2015–2023 · strength 0.99
  2. Kyoichi Takaori · 14 shared papers, 2011–2022 · strength 0.89
  3. Akihisa Fukuda · 6 shared papers, 2018–2023 · strength 0.65
  4. Hiroshi Seno · 5 shared papers, 2018–2022 · strength 0.53
  5. Etsuro Hatano · 4 shared papers, 2017–2023 · strength 0.47
  6. Masashi Kanai · 6 shared papers, 2014–2023 · strength 0.45
  7. Michio Yoshimura · 4 shared papers, 2014–2023 · strength 0.42
  8. Takashi Mizowaki · 4 shared papers, 2014–2023 · strength 0.42
  9. Kazuyuki Nagai · 3 shared papers, 2020–2023 · strength 0.38
  10. Tsutomu Chiba · 6 shared papers, 2014–2021 · strength 0.37
  11. Shigeo Takaishi · 3 shared papers, 2019–2022 · strength 0.35
  12. Asahi Sato · 4 shared papers, 2016–2022 · strength 0.35
  13. Yuichiro Uchida · 3 shared papers, 2017–2022 · strength 0.28
  14. Kozo Ikuta · 3 shared papers, 2018–2021 · strength 0.25
  15. Takahisa Maruno · 3 shared papers, 2018–2021 · strength 0.25
  16. Motoyuki Tsuda · 3 shared papers, 2018–2021 · strength 0.25
  17. Satoshi Ogawa · 3 shared papers, 2018–2021 · strength 0.25
  18. Shinya Okumura · 3 shared papers, 2015–2020 · strength 0.22
  19. Kenji Masuo · 2 shared papers, 2019–2021 · strength 0.21
  20. Yuzo Kodama · 4 shared papers, 2014–2017 · strength 0.18
  21. Shintaro Yagi · 2 shared papers, 2017–2020 · strength 0.17
  22. Sadanori Watanabe · 1 shared paper, 2022 · strength 0.15
  23. Yoshito Kimura · 2 shared papers, 2018–2019 · strength 0.14
  24. Reo Hamaguchi · 1 shared paper, 2020 · strength 0.13
  25. Hiromi Wada · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.